ArticleBMC nephrology2026
Serum metabolites in relation to kidney function in non-transplant and kidney transplant settings using gas chromatography-mass spectrometry.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMetabolic disorders are highly prevalent in patients with native and transplanted chronic kidney disease (CKD). However, little is known about the metabolic similarities and differences associated with declining kidney function between non-transplant patients and kidney transplant recipients (KTRs).
methodsThis cross-sectional study employed gas chromatography-mass spectrometry to compare serum metabolomic profiles among native CKD subgroups and KTR subgroups, aiming to identify differential metabolites associated with kidney dysfunction in both clinical settings.
results11 and 13 metabolites were associated with kidney dysfunction in native CKD patients and KTRs, respectively. Among these, L-tryptophan, D-lyxose, xylitol, erythritol, 3,4-dihydroxybutanoic acid and 2,4-dihydroxybutanoic acid were selected as common differential metabolites in both cohorts. Pathway analysis revealed that the pentose and glucuronate interconversions pathway was significantly affected in native CKD patients, whereas phenylalanine, tyrosine, and tryptophan biosynthesis pathway and tyrosine metabolism pathway were the most affected pathways in KTRs. Further comparisons between native CKD and KTRs who were at the same kidney dysfunction stages demonstrated that KTRs showed significantly higher levels of malic acid, but lower levels of D-allose compared to native CKD patients.
conclusionsOur study not only identified the 6 metabolites associated with kidney function in both non-transplant patients and KTRs, but also determined 5 and 7 metabolites that were specifically associated with kidney dysfunction in native CKD patients and KTRs, respectively. These data suggest that the metabolic process may be influenced by the unique characteristics of kidney transplantation, such as allogeneic immunity and immunosuppressive drugs, in KTRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.